Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
10.10B
Market cap10.10B
Price-Earnings ratio
27.89
Price-Earnings ratio27.89
Dividend yield
Dividend yield
Average volume
1.60M
Average volume1.60M
High today
$82.99
High today$82.99
Low today
$80.94
Low today$80.94
Open price
$81.44
Open price$81.44
Volume
1.66M
Volume1.66M
52 Week high
$82.99
52 Week high$82.99
52 Week low
$57.68
52 Week low$57.68

Stock Snapshot

With a market cap of 10.1B, Halozyme Therapeutics(HALO) trades at $82.00. The stock has a price-to-earnings ratio of 27.89.

As of 2026-07-26, Halozyme Therapeutics(HALO) stock has fluctuated between $80.94 and $82.99. The current price stands at $82.00, placing the stock +1.3% above today's low and -1.2% off the high.

The Halozyme Therapeutics(HALO)'s current trading volume is 1.66M, compared to an average daily volume of 1.6M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $57.68 at its lowest and $82.99 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $57.68 at its lowest and $82.99 at its peak.

HALO News

TipRanks 1d
Halozyme Therapeutics Q1 2025 Earnings Report - Results, Call & Slides - TipRanks

...

Halozyme Therapeutics Q1 2025 Earnings Report - Results, Call & Slides - TipRanks
Simply Wall St 5d
Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte’s Pipeline Strategy?

In July 2026, Halozyme Therapeutics announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989, using...

Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte’s Pipeline Strategy?
Simply Wall St 5d
Halozyme Therapeutics Lands Incyte Deal On A Valuation That Still Looks Undervalued

Halozyme Therapeutics (HALO) drew fresh attention after signing a global partnership and licence agreement with Incyte to apply its Enhanze technology to subcut...

Halozyme Therapeutics Lands Incyte Deal On A Valuation That Still Looks Undervalued

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

More HALO News

Nasdaq 6d
Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology

(RTTNews) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement...

Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology
TipRanks 6d
Halozyme announces global collaboration, license agreement with Incyte

Halozyme Therapeutics (HALO) announced that it has entered into a global collaboration and license agreement with Incyte (INCY) to evaluate additional subcutane...

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.